<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38449882</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Hyperbaric oxygen effectively addresses the pathophysiology of long COVID: clinical review.</ArticleTitle><Pagination><StartPage>1354088</StartPage><MedlinePgn>1354088</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1354088</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2024.1354088</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The World Health Organization defines long COVID as "the continuation or development of new symptoms 3&#x2009;months after the initial SARS-CoV-2 infection, with these symptoms lasting for at least 2&#x2009;months with no other explanation." Estimations of approximately 50 million individuals suffer from long COVID, reporting low health-related quality of life. Patients develop ongoing persistent symptoms that continue for more than 12&#x2009;weeks that are not explained by another alternative diagnosis. To date, no current therapeutics are effective in treating the underlying pathophysiology of long COVID.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">A comprehensive literature search using PubMed and Google Scholar was conducted and all available articles from November 2021 to January 2024 containing keywords long covid and hyperbaric oxygen were reviewed. These published studies, including case series and randomized trials, demonstrate that utilizing Hyperbaric Oxygen Therapy (HBO) provided significant improvement in patients with long COVID.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">A large cohort of patients suffer from long COVID or post-COVID-19 syndrome after recovery from their acute infection with no effective treatment options. HBO is a safe treatment and may provide benefit for this population and should continue to be researched for adjunctive treatment of long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Katz, Wainwright, Kelly, Albert and Byrne.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Alan A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Hyperbaric Medical Solutions, New York, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Orlando College of Osteopathic Medicine, Winter Garden, FL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wainwright</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Greenwich Hospital, Yale New Haven Health System, New Haven, CT, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>University of Alabama at Birmingham, Heersink School of Medicine, Birmingham, AL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Orlando College of Osteopathic Medicine, Winter Garden, FL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byrne</LastName><ForeName>Rosemary</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Hyperbaric Medical Solutions, New York, NY, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HBO</Keyword><Keyword MajorTopicYN="N">hyperbaric</Keyword><Keyword MajorTopicYN="N">hyperbaric oxygen therapy</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-COVID-19 syndrome</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>7</Day><Hour>4</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38449882</ArticleId><ArticleId IdType="pmc">PMC10916685</ArticleId><ArticleId IdType="doi">10.3389/fmed.2024.1354088</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Marshall M. The four most urgent questions about long COVID. Nature. (2021) 594:168&#x2013;70. doi: 10.1038/d41586-021-01511-z, PMID: ,</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-01511-z</ArticleId><ArticleId IdType="pubmed">34108700</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. . Post-acute COVID-19 syndrome. Nat Med. (2021) 27:601&#x2013;15. doi: 10.1038/s41591-021-01283-z, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. (2021) 9:129. doi: 10.1016/S2213-2600(21)00031-X, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00031-X</ArticleId><ArticleId IdType="pmc">PMC7832375</ArticleId><ArticleId IdType="pubmed">33453162</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  (2022). Post COVID-19 condition (long COVID). Available at: https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition</Citation></Reference><Reference><Citation>Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, et al. . 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. (2021) 76:396&#x2013;8. doi: 10.1136/thoraxjnl-2020-215818, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-215818</ArticleId><ArticleId IdType="pmc">PMC7615158</ArticleId><ArticleId IdType="pubmed">33172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra V, Flanders SA, O&#x2019;Malley M. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med. (2020) 174:576&#x2013;8. doi: 10.7326/M20-5661</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-5661</ArticleId><ArticleId IdType="pmc">PMC7707210</ArticleId><ArticleId IdType="pubmed">33175566</ArticleId></ArticleIdList></Reference><Reference><Citation>Yomogida K, Zhu S, Rubino F, Figueroa W, Balanji N, Holman E. Post-Acute Sequelae of SARS-CoV-2 Infection Among Adults Aged &#x2265;18 Years - Long Beach, California, April 1-December 10, 2020. MMWR Morb Mortal Wkly Rep. (2021) 70:1274&#x2013;1277. doi: 10.15585/mmwr.mm7037a2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7037a2</ArticleId><ArticleId IdType="pmc">PMC8445372</ArticleId><ArticleId IdType="pubmed">34529639</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. (2022) 23:194&#x2013;202. doi: 10.1038/s41590-021-01104-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond). (2021) 53:737&#x2013;54. doi: 10.1080/23744235.2021.1924397, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2021.1924397</ArticleId><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. . Immunological dysfunction persists for 8 months following initial mild&#x2013;moderate SARS-CoV-2 infection. Nat Immunol. (2022) 23:210&#x2013;6. doi: 10.1038/s41590-021-01113-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlsson AC, Humbert M, Buggert M. The known unknowns of T cell immunity to COVID. Sci Immunol. (2020) 5:19. doi: 10.1126/sciimmunol.abe8063, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abe8063</ArticleId><ArticleId IdType="pubmed">33208380</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavakolpour S, Rakhshandehroo T, Wei EX, Rashidian M. Lymphopenia during the COVID-19 infection: what it shows and what can be learned. Immunol Lett. (2020) 225:31&#x2013;2. doi: 10.1016/j.imlet.2020.06.013, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2020.06.013</ArticleId><ArticleId IdType="pmc">PMC7305732</ArticleId><ArticleId IdType="pubmed">32569607</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni E, Valoriani A, Cei F, Lamanna R, Gelli AMG, Ciambotti B, et al. . Interleukin-6 as prognosticator in patients with COVID-19. J Infect. (2020) 81:452&#x2013;82. doi: 10.1016/j.jinf.2020.06.008, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.06.008</ArticleId><ArticleId IdType="pmc">PMC7278637</ArticleId><ArticleId IdType="pubmed">32526326</ArticleId></ArticleIdList></Reference><Reference><Citation>Passos FRS, Heimfarth L, Monteiro BS, Corr&#xea;a CB, Moura TR, AAS A, et al. . Oxidative stress and inflammatory markers in patients with COVID-19: potential role of RAGE, HMGB1, GFAP and COX-2 in disease severity. Int Immunopharmacol. (2022) 104:108502. doi: 10.1016/j.intimp.2021.108502, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.108502</ArticleId><ArticleId IdType="pmc">PMC8730710</ArticleId><ArticleId IdType="pubmed">35063743</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossato MS, Brilli E, Ferri N, Giordano G, Tarantino G. Observational study on the benefit of a nutritional supplement, supporting immune function and energy metabolism, on chronic fatigue associated with the SARS-CoV-2 post-infection progress. Clin Nutr ESPEN. (2021) 46:510&#x2013;8. doi: 10.1016/j.clnesp.2021.08.031, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnesp.2021.08.031</ArticleId><ArticleId IdType="pmc">PMC8420132</ArticleId><ArticleId IdType="pubmed">34857243</ArticleId></ArticleIdList></Reference><Reference><Citation>Oronsky B, Larson C, Hammond TC, Oronsky A, Kesari S, Lybeck M, et al. . A review of persistent post-COVID syndrome (PPCS). Clin Rev Allergy Immunol. (2023) 64:66&#x2013;74. doi: 10.1007/s12016-021-08848-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-021-08848-3</ArticleId><ArticleId IdType="pmc">PMC7896544</ArticleId><ArticleId IdType="pubmed">33609255</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. (2023) 21:133&#x2013;46. doi: 10.1038/s41579-022-00846-2, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Camporesi EM, Bosco G. Mechanisms of action of hyperbaric oxygen therapy. Undersea Hyperb Med. (2014) 41:247&#x2013;52. PMID:</Citation><ArticleIdList><ArticleId IdType="pubmed">24984320</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedetoft M, Garred P, Madsen MB, Hyldegaard O. Hyperbaric oxygen treatment is associated with a decrease in cytokine levels in patients with necrotizing soft-tissue infection. Physiol Rep. (2021) 9:e14757. doi: 10.14814/phy2.14757, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.14814/phy2.14757</ArticleId><ArticleId IdType="pmc">PMC7957267</ArticleId><ArticleId IdType="pubmed">33719215</ArticleId></ArticleIdList></Reference><Reference><Citation>Schottlender N, Gottfried I, Ashery U. Hyperbaric oxygen treatment: effects on mitochondrial function and oxidative stress. Biomol Ther. (2021) 11:1827. doi: 10.3390/biom11121827, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11121827</ArticleId><ArticleId IdType="pmc">PMC8699286</ArticleId><ArticleId IdType="pubmed">34944468</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldmeier JJ, Kirby JP, Buckey JC, Denham DW, Evangelista JS, Gelly H, et al. . Physiologic and biochemical rationale for treating COVID-19 patients with hyperbaric oxygen. Undersea Hyperb Med. (2021) 48:1&#x2013;12. doi: 10.22462/01.03.2021.1, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.22462/01.03.2021.1</ArticleId><ArticleId IdType="pubmed">33648028</ArticleId></ArticleIdList></Reference><Reference><Citation>Zant AE, Figueroa XA, Paulson CP, Wright JK. Hyperbaric oxygen therapy to treat lingering COVID-19 symptoms. Undersea Hyperb Med. (2022) 49:333&#x2013;9. doi: 10.22462/05.06.2022.7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.22462/05.06.2022.7</ArticleId><ArticleId IdType="pubmed">36001566</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins T, Gonevski M, Clark C, Baitule S, Sharma K, Magar A, et al. . Hyperbaric oxygen therapy for the treatment of long COVID: early evaluation of a highly promising intervention. Clin Med (Lond). (2021) 21:e629&#x2013;32. doi: 10.7861/clinmed.2021-0462, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2021-0462</ArticleId><ArticleId IdType="pmc">PMC8806311</ArticleId><ArticleId IdType="pubmed">34862223</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilberman-Itskovich S, Catalogna M, Sasson E, Elman-Shina K, Hadanny A, Lang E, et al. . Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial. Sci Rep. (2022) 12:11252. doi: 10.1038/s41598-022-15565-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-15565-0</ArticleId><ArticleId IdType="pmc">PMC9276805</ArticleId><ArticleId IdType="pubmed">35821512</ArticleId></ArticleIdList></Reference><Reference><Citation>Catalogna M, Sasson E, Hadanny A, Parag Y, Zilberman-Itskovich S, Efrati S. Effects of hyperbaric oxygen therapy on functional and structural connectivity in post-COVID-19 condition patients: a randomized, sham-controlled trial. Neuroimage Clin. (2022) 36:103218. doi: 10.1016/j.nicl.2022.103218, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2022.103218</ArticleId><ArticleId IdType="pmc">PMC9528018</ArticleId><ArticleId IdType="pubmed">36208548</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjellberg A, Hassler A, Bostr&#xf6;m E, El Gharbi S, Al-Ezerjawi S, Kowalski J, et al. . Hyperbaric oxygen therapy for long COVID (HOT-LoCO), an interim safety report from a randomised controlled trial. BMC Infect Dis. (2023) 23:33. doi: 10.1186/s12879-023-08002-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08002-8</ArticleId><ArticleId IdType="pmc">PMC9854077</ArticleId><ArticleId IdType="pubmed">36670365</ArticleId></ArticleIdList></Reference><Reference><Citation>Leitman M, Fuchs S, Tyomkin V, Hadanny A, Zilberman-Itskovich S, Efrati S. The effect of hyperbaric oxygen therapy on myocardial function in post-COVID-19 syndrome patients: a randomized controlled trial. Sci Rep. (2023) 13:9473. doi: 10.1038/s41598-023-36570-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-36570-x</ArticleId><ArticleId IdType="pmc">PMC10257166</ArticleId><ArticleId IdType="pubmed">37301934</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrakic-Sposta S, Vezzoli A, Garetto G, Paganini M, Camporesi E, Giacon TA, et al. . Hyperbaric oxygen therapy counters oxidative stress/inflammation-driven symptoms in long COVID-19 patients: preliminary outcomes. Meta. (2023) 13:1032. doi: 10.3390/metabo13101032, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo13101032</ArticleId><ArticleId IdType="pmc">PMC10608857</ArticleId><ArticleId IdType="pubmed">37887357</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitala D, &#x141;abu&#x15b; W, Kozielski J, Strzelec P, Nowak M, Knefel G, et al. . Preliminary research on the effect of hyperbaric oxygen therapy in patients with post-COVID-19 syndrome. J Clin Med. (2023) 12:308. doi: 10.3390/jcm12010308, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12010308</ArticleId><ArticleId IdType="pmc">PMC9821575</ArticleId><ArticleId IdType="pubmed">36615108</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaiyat AM, Sasson E, Wang Z, Khairy S, Ginzarly M, Qureshi U, et al. . Hyperbaric oxygen treatment for long coronavirus disease-19: a case report. J Med Case Rep. (2022) 16:80. doi: 10.1186/s13256-022-03287-w, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13256-022-03287-w</ArticleId><ArticleId IdType="pmc">PMC8848789</ArticleId><ArticleId IdType="pubmed">35168680</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindenmann J, Porubsky C, Okresa L, Klemen H, Mykoliuk I, Roj A, et al. . Immediate and Long-Term Effects of Hyperbaric Oxygenation in Patients with Long COVID-19 Syndrome Using SF-36 Survey and VAS Score: A Clinical Pilot Study. J Clin Med. (2023) 12:6253. doi: 10.3390/jcm12196253</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12196253</ArticleId><ArticleId IdType="pmc">PMC10573231</ArticleId><ArticleId IdType="pubmed">37834897</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjellberg A, Abdel-Halim L, Hassler A, El Gharbi S, Al-Ezerjawi S, Bostr&#xf6;m E, et al. . Hyperbaric oxygen for treatment of long COVID-19 syndrome (HOT-LoCO): protocol for a randomised, placebo-controlled, double-blind, phase II clinical trial. BMJ Open. (2022) 12:e061870. doi: 10.1136/bmjopen-2022-061870</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-061870</ArticleId><ArticleId IdType="pmc">PMC9638753</ArticleId><ArticleId IdType="pubmed">36323462</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>